Previous 10 | Next 10 |
2018 seems to be ending on a bad note in the markets. December is setting the wrong kind of records, and Q4 has been a bumpy one in general. This is what happens in the stock market sometimes, but it's been easy to forget over the decade-long bull market. We're using the end of the year as a...
Gainers: PSDO +9.1% . ASNS +4.9% . TVIX +4.6% . MRNS +3.1% . M +1.6% . More news on: Presidio, Arsanis, Inc., VelocityShares Daily 2x VIX Short-Term ETN, , Stocks on the move, News on ETFs, Read more ...
Introduction Marinus Pharmaceuticals ( MRNS ) on December 10 announced top-line results from their PhII trials evaluating both IV and oral ganaxolone for the treatment of post-partum depression ('PPD'). PPD occurs in an estimated 200-550k women every year in the U.S., with no approved t...
Note: This article, edited for public distribution, was first provided to members of my exclusive marketplace on December 11th, when shares of Marinus (MRNS) were trading at ~$5.20. Preface Within my exclusive marketplace, The Formula , I look for assets that provide therapeutic dif...
Nutrisystem (NASDAQ: NTRI ) +31% on cash and stock offer from Tivity Health. More news on: Nutrisystem Inc, Mitek Systems Inc., Axsome Therapeutics, Stocks on the move, , Read more ...
Marinus Pharmaceuticals (NASDAQ: MRNS ) is up 35% premarket on average volume in reaction to its announcement of positive results from Phase 2 studies evaluating intravenously administered ganaxolone in women with postpartum depression (PPD). More news on: Marinus Pharmaceuti...
Ganaxolone was safe and well-tolerated Ganaxolone IV demonstrated fast-acting, robust and durable efficacy Interim data with ganaxolone oral supports IV to oral administration Conference call to be held today at 8:30 AM ET RADNOR, Pa., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Mar...
NEW YORK, Nov. 06, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Oil States International, Inc. (NYSE:OIS), Brightcove Inc. (NASDAQ:BCOV),...
Friday's thumbs up from an FDA advisory committee on Sage Therapeutics' (NASDAQ: SAGE ) GABA modulator brexanolone for postpartum depression (PPD) could stoke buying in Marinus Pharmaceuticals (NASDAQ: MRNS ). It is also developing a GABA modulator, ganaxolone, for PPD, albeit with a longer ...
Understanding Denali as an investment I previously explored the over-arching potential of the unique 'transport vehicle' platform perfected by Denali Therapeutics ( DNLI ) for the shuttling of large-molecule therapeutics across the blood-brain-barrier. Since I posted that analysis, the ...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...